The Grand Challenge for the Future

[1]  M. Lipsitch,et al.  Vaccination against colonizing bacteria with multiple serotypes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Siber.  Pneumococcal disease: prospects for a new generation of vaccines. , 1994, Science.

[3]  H. Ochs,et al.  Diminished expression of CD40 ligand by activated neonatal T cells. , 1995, The Journal of clinical investigation.

[4]  Yiming Shao,et al.  Enhanced: The Need for a Global HIV Vaccine Enterprise , 2003, Science.

[5]  T. Whiteside,et al.  Generation of PSA‐reactive effector cells after vaccination with a PSA‐based vaccine in patients with prostate cancer , 2000, The Prostate.

[6]  P. Rhodes,et al.  Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. , 1996, Pediatrics.

[7]  M. Clerici,et al.  Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages. , 1993, The Journal of clinical investigation.

[8]  J. Fagerberg,et al.  Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies , 1995, Cancer Immunology, Immunotherapy.

[9]  Michael P. Todaro,et al.  World Development Report 1990. , 1990 .

[10]  R. Rabin,et al.  CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection. , 1998, Journal of immunology.

[11]  E. Remmerswaal,et al.  Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. , 2003, Blood.

[12]  S. Jaffar,et al.  Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants , 1997, The Lancet.

[13]  Measles Vaccines , 1998, Drug safety.

[14]  L. Herzenberg,et al.  The ontogeny and functional characteristics of human B-1 (CD5+ B) cells. , 1992, International immunology.

[15]  A. Hinman,et al.  Haemophilus influenzae type B conjugate vaccine , 1988 .

[16]  E. Wiertz,et al.  Viral immune evasion: a masterpiece of evolution , 2002, Immunogenetics.

[17]  J. Farrar,et al.  Type I interferons and T helper development. , 2000, Immunology today.

[18]  M. Lai,et al.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. , 1997, The New England journal of medicine.

[19]  P. Lipsky,et al.  CD40 ligand is expressed and functional on activated neonatal T cells. , 1996, Journal of immunology.

[20]  M. Goldman,et al.  Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. , 2004, Blood.

[21]  J. White,et al.  Structure and properties of aluminum-containing adjuvants. , 1995, Pharmaceutical biotechnology.

[22]  S. Hem.  Elimination of aluminum adjuvants. , 2002, Vaccine.

[23]  C. Alving,et al.  Preparation and Use of Liposomes in Immunological Studies , 1993 .

[24]  Rabinovich Nr.  Are we there yet? The road to a malaria vaccine. , 2002 .

[25]  A. Danchin,et al.  The Severe Acute Respiratory Syndrome , 2003 .

[26]  H. Grey,et al.  The minimal number of antigen‐major histocompatibility complex class II complexes required for activation of naive and primed T cells , 1997, European journal of immunology.

[27]  D. Shalala,et al.  Protecting research subjects--what must be done. , 2000, The New England journal of medicine.

[28]  L. Nencioni,et al.  Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa. , 1991, Vaccine.

[29]  M. Rennels,et al.  Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. , 1997, The Journal of infectious diseases.

[30]  M. Biffi,et al.  Selective Expression of an Interleukin-12 Receptor Component by Human T Helper 1 Cells , 1997, Journal of Experimental Medicine.

[31]  J. Eskola,et al.  Pneumococcal conjugate vaccines. , 1999, The Pediatric infectious disease journal.

[32]  M. Gréco,et al.  The future of vaccines: an industrial perspective. , 2001, Vaccine.

[33]  M. Nielsen,et al.  Persistent Subcutaneous Nodules in Children Hyposensitized with Aluminium‐Containing Allergen Extracts , 1985, Allergy.

[34]  R. Proia,et al.  Membrane receptors for bacterial toxins , 1983, Microbiological reviews.

[35]  J. Banchereau,et al.  How dendritic cells and microbes interact to elicit or subvert protective immune responses. , 2002, Current opinion in immunology.

[36]  Man-Huei Chang,et al.  Summary of notifiable diseases--United States, 2002. , 2004, MMWR. Morbidity and mortality weekly report.

[37]  M. Kubin,et al.  High Level Interleukin-12 Production, but Diminished Interferon-γ Production, by Cord Blood Mononuclear Cells , 1997, Pediatric Research.

[38]  M. Eaton,et al.  JAUNDICE IN ARMY PERSONNEL IN THE WESTERN REGION OF THE UNITED STATES AND ITS RELATION TO VACCINATION AGAINST YELLOW FEVERPART I , 1944 .

[39]  J. Mcghee,et al.  Cholera toxin activates dendritic cells through dependence on GM1‐ganglioside which is mediated by NF‐κB translocation , 2003, European journal of immunology.

[40]  H. Peltola.  Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. , 2000, Clinical microbiology reviews.

[41]  R. Mahoney,et al.  The introduction of new vaccines into developing countries. , 1999, Vaccine.

[42]  J. Lang,et al.  Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children , 2004, The Pediatric infectious disease journal.

[43]  J. V. Ravetch,et al.  IgG Fc receptors. , 2001, Annual review of immunology.

[44]  R. Couch.  Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. , 2004, The New England journal of medicine.

[45]  H. Gravelle,et al.  Discounting for health effects in cost-benefit and cost-effectiveness analysis. , 2001, Health economics.

[46]  H. Jick,et al.  Haemophilus influenzae vaccine. , 1995, The British journal of general practice : the journal of the Royal College of General Practitioners.

[47]  M. Leinonen,et al.  Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. , 1991, The Journal of infectious diseases.

[48]  W. Hop,et al.  Flow cytometric analysis of the Vbeta repertoire in healthy controls. , 2000, Cytometry.

[49]  J. G. Fitzgerald,et al.  DIPHTHERIA TOXOID AS AN IMMUNIZING AGENT. , 1927, Canadian Medical Association journal.

[50]  R. Rappuoli,et al.  The design of vaccines against Helicobacter pylori and their development. , 2001, Annual review of immunology.

[51]  C. Elson,et al.  Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. , 1984, Journal of immunology.

[52]  P. Libby,et al.  The CD40/CD154 receptor/ligand dyadRID="†"ID="†" Review , 2001, Cellular and Molecular Life Sciences CMLS.

[53]  K. Dabbagh,et al.  Decreased CD154 expression by neonatal CD4+ T cells is due to limitations in both proximal and distal events of T cell activation. , 2003, International immunology.

[54]  G. Gerna,et al.  Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. , 1998, The Journal of infectious diseases.

[55]  A. Schuchat.  Group B streptococcus , 1999, The Lancet.

[56]  R. Ellis,et al.  Technologies for the design, discovery, formulation and administration of vaccines. , 2001, Vaccine.

[57]  C. P. Farrington,et al.  Lack of association between intussusception and oral polio vaccine in Cuban children , 2004, European Journal of Epidemiology.

[58]  D. Karp,et al.  Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. , 2002, Immunity.

[59]  Holden T Maecker,et al.  Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. , 2002, The Journal of infectious diseases.

[60]  H. Inskip,et al.  Cost-effectiveness of hepatitis B vaccine in The Gambia. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[61]  K. Rajewsky.  Clonal selection and learning in the antibody system , 1996, Nature.

[62]  J. White,et al.  Solubilization of aluminum-containing adjuvants by constituents of interstitial fluid. , 1991, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

[63]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[64]  J. Clemens,et al.  Translational research to assist policy decisions about introducing new vaccines in developing countries. , 2004, Journal of health, population, and nutrition.

[65]  H. Käyhty,et al.  Current State of Pneumococcal Vaccines , 2002, Scandinavian journal of immunology.

[66]  B. Greenwood,et al.  A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. , 1995, The Journal of infectious diseases.

[67]  T. Uchiyama,et al.  Evidence for immunologic immaturity of cord blood T cells. Cord blood T cells are susceptible to tolerance induction to in vitro stimulation with a superantigen. , 1995, Journal of immunology.

[68]  A. Chu,et al.  Characterization of immature T cell subpopulations in neonatal blood. , 1984, Blood.

[69]  H. Zola,et al.  The antigen receptor complex on cord B lymphocytes , 1997, Immunology.

[70]  S. Plotkin,et al.  A new typhoid vaccine composed of the Vi capsular polysaccharide. , 1995, Archives of internal medicine.

[71]  Y. Poovorawan,et al.  Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. , 1992, The Pediatric infectious disease journal.

[72]  M. Newport,et al.  Influence of Mycobacterium bovis Bacillus Calmette-Guérin on Antibody and Cytokine Responses to Human Neonatal Vaccination1 , 2002, The Journal of Immunology.

[73]  R G Record,et al.  An interpretation of the modern rise of population in Europe. , 1972, Population studies.

[74]  C. Stuart-harris,et al.  Adjuvant influenza vaccines. , 1969, Bulletin of the World Health Organization.

[75]  G. Ippolito,et al.  Regulation of the antibody repertoire through control of HCDR3 diversity. , 1998, Vaccine.

[76]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[77]  R. Hromas,et al.  Regulation of naïve fetal T-cell migration by the chemokines Exodus-2 and Exodus-3. , 1999, Immunology letters.

[78]  Michael K Paasche-Orlow,et al.  Readability standards for informed-consent forms as compared with actual readability. , 2003, The New England journal of medicine.

[79]  Obi L. Griffith,et al.  The Genome Sequence of the SARS-Associated Coronavirus , 2003, Science.

[80]  C. Wolf‐peeters,et al.  Epidermal Langerhans' Cells and Dermal Dendritic Cells in Human Fetal and Neonatal Skin: An Immunohistochemical Study , 1987, Pediatric dermatology.

[81]  J. Ehreth.  The global value of vaccination. , 2003, Vaccine.

[82]  F. Simondon,et al.  Practical experiences in obtaining informed consent for a vaccine trial in rural Africa. , 1997, The New England journal of medicine.

[83]  Robert T. Chen,et al.  Population-based study of rotavirus vaccination and intussusception , 2001, The Pediatric infectious disease journal.

[84]  David Goldblatt,et al.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. , 2003, Vaccine.

[85]  H. Stapleton,et al.  Qualitative study of evidence based leaflets in maternity care , 2002, BMJ : British Medical Journal.

[86]  Y. Maldonado,et al.  Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. , 1995, Pediatrics.

[87]  J. Kelso,et al.  Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. , 1993, The Journal of allergy and clinical immunology.

[88]  Jong‐Wha Lee,et al.  Globalization and Disease: The Case of SARS , 2004, Asian Economic Papers.

[89]  R. Rappuoli,et al.  Reverse vaccinology, a genome-based approach to vaccine development. , 2001 .

[90]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[91]  李幼升,et al.  Ph , 1989 .

[92]  R. Zinkernagel,et al.  Efficient immune responses in mice lacking N‐region diversity , 1995, European journal of immunology.

[93]  S. Riddell,et al.  T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. , 2000, The Journal of antimicrobial chemotherapy.

[94]  J. Nielsen,et al.  Impaired progenitor cell function in HIV-negative infants of HIV-positive mothers results in decreased thymic output and low CD4 counts. , 2001, Blood.

[95]  T. Popović,et al.  Reemergence, in southwestern Alaska, of invasive Haemophilus influenzae type b disease due to strains indistinguishable from those isolated from vaccinated children. , 2002, The Journal of infectious diseases.

[96]  M. Wadhwa,et al.  Sustained Expression of CD154 (CD40L) and Proinflammatory Cytokine Production by Alloantigen-Stimulated Umbilical Cord Blood T Cells1 , 2000, The Journal of Immunology.

[97]  S. Hem,et al.  Aluminum Compounds Used as Adjuvants in Vaccines , 1990, Pharmaceutical Research.

[98]  J. Warner,et al.  Expression of CD21 and CD23 during Human Fetal Development , 2002, Pediatric Research.

[99]  Y. Maldonado,et al.  IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. , 1999, Journal of immunology.

[100]  D. Ambrosino,et al.  Human polysaccharide-specific B cells are responsive to pokeweed mitogen and IL-6. , 1990, Journal of immunology.

[101]  D. Nalin,et al.  Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers. , 1998, Vaccine.

[102]  M. Osterholm,et al.  Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. , 1993, JAMA.

[103]  R. Provenzano,et al.  Immunization and antibody response in the newborn infant. I. Pertussis inoculation within twenty-four hours of birth. , 1965, The New England journal of medicine.

[104]  M. Petersen,et al.  Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. , 2003, The Journal of infectious diseases.

[105]  E. Zell,et al.  Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. , 1993, JAMA.

[106]  J. Sullivan,et al.  HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. , 1995, Journal of immunology.

[107]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[108]  W. Edmunds,et al.  The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa. , 2000, Health policy and planning.

[109]  Inacio Mandomando,et al.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.

[110]  N. Halsey.  The science of evaluation of adverse events associated with vaccination. , 2002, Seminars in pediatric infectious diseases.

[111]  R. Geha,et al.  Decreased expression of the ligand for CD40 in newborn lymphocytes , 1994, European journal of immunology.

[112]  M. Weinstein,et al.  Foundations of cost-effectiveness analysis for health and medical practices. , 1977, The New England journal of medicine.

[113]  L. Lanier,et al.  Killer cell inhibitory receptor expression by T cells. , 1998, Current topics in microbiology and immunology.

[114]  B. Greenwood,et al.  The microepidemiology of malaria and its importance to malaria control. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[115]  D. Goldblatt.  Immunisation and the maturation of infant immune responses. , 1998, Developments in biological standardization.

[116]  C. Pitcher,et al.  Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. , 1997, The Journal of clinical investigation.

[117]  J. Schlom,et al.  Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. , 1992, Cancer research.

[118]  Nick Andrews,et al.  Thimerosal Exposure in Infants and Developmental Disorders: A Retrospective Cohort Study in the United Kingdom Does Not Support a Causal Association , 2004, Pediatrics.

[119]  Ben A. van Hout,et al.  Discounting costs and effects: a reconsideration. , 1998 .

[120]  F. Borràs,et al.  Identification of both myeloid CD11c+ and lymphoid CD11c− dendritic cell subsets in cord blood , 2001, British journal of haematology.

[121]  S. Lockhart,et al.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media. , 2001, The New England journal of medicine.

[122]  E. Mishan.  Evaluation of Life and Limb: A Theoretical Approach , 1971, Journal of Political Economy.

[123]  A. Cross,et al.  Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans. , 1991, The Journal of infectious diseases.

[124]  C. D. de Quadros,et al.  [Introduction of a conjugate vaccine against Hib in Chile and Uruguay]. , 1999, Revista panamericana de salud publica = Pan American journal of public health.

[125]  S. Hem,et al.  The Importance of Surface Charge in the Optimization of Antigen–Adjuvant Interactions , 1991, Pharmaceutical Research.

[126]  D. Crook,et al.  The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. , 1995, The Journal of infectious diseases.

[127]  J. White,et al.  Predicting the adsorption of proteins by aluminium-containing adjuvants. , 1991, Vaccine.

[128]  N. Ariel,et al.  Generation of Yersinia pestis Attenuated Strains by Signature-Tagged Mutagenesis in Search of Novel Vaccine Candidates , 2004, Infection and Immunity.

[129]  D. Lilleri,et al.  Human Cytomegalovirus Proteins pp65 and Immediate Early Protein 1 Are Common Targets for CD8+ T Cell Responses in Children with Congenital or Postnatal Human Cytomegalovirus Infection1 , 2004, The Journal of Immunology.

[130]  C. Tournay,et al.  Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. , 2000, Transplantation.

[131]  E. Rothstein,et al.  Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. , 2004, Vaccine.

[132]  J. Vekemans,et al.  Deficient IL-12(p35) Gene Expression by Dendritic Cells Derived from Neonatal Monocytes1 , 2001, The Journal of Immunology.

[133]  G. Cloud,et al.  Working parents: the impact of day care and breast-feeding on cytomegalovirus infections in offspring. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[134]  H. Hallander,et al.  Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine , 1997, The Lancet.

[135]  Douglas Rg.  Fostering partnerships for vaccine development: a delicate fabric. , 1996 .

[136]  J. Even,et al.  Human fetuses are able to mount an adultlike CD8 T-cell response. , 2002, Blood.

[137]  C P Farrington,et al.  Control without separate controls: evaluation of vaccine safety using case-only methods. , 2004, Vaccine.

[138]  J. Martin,et al.  New tendencies and strategies in international immunisation: GAVI and The Vaccine Fund. , 2003, Vaccine.

[139]  S. Cryz,et al.  Immunogenicity of new virosome influenza vaccine in elderly people , 1994, The Lancet.

[140]  E. Ward,et al.  FcRn: the MHC class I-related receptor that is more than an IgG transporter. , 1997, Immunology today.

[141]  T. Coates,et al.  Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. , 2001, Clinical therapeutics.

[142]  L. Corey,et al.  Diminished Interferon-γ and Lymphocyte Proliferation in Neonatal and Postpartum Primary Herpes Simplex Virus Infection , 1992 .

[143]  A. Creese,et al.  Cost-effectiveness appraisal of immunization programmes. , 1982, Bulletin of the World Health Organization.

[144]  F. Buseyne,et al.  Cytotoxic T lymphocytes generation capacity in early life with particular reference to HIV. , 1998, Vaccine.

[145]  M. Angell.  The ethics of clinical research in the Third World. , 1997, The New England journal of medicine.

[146]  D. Jamison.  Investing in Health , 2006 .

[147]  Penelope H Dennehy.  Rotavirus vaccines--an update. , 2007, Vaccine.

[148]  L. Nencioni,et al.  Mutants of pertussis toxin suitable for vaccine development. , 1989, Science.

[149]  M. Hochhauser.  The Informed Consent Form: Document Development and Evaluation , 2000 .

[150]  P. Paradiso,et al.  Maternal immunization: the influence of liability issues on vaccine development. , 2001, Vaccine.

[151]  P. Engstrom,et al.  Augmentation of the human immune response by cyclophosphamide. , 1982, Cancer research.

[152]  S. Plotkin.  Vaccines, vaccination, and vaccinology. , 2003, The Journal of infectious diseases.

[153]  L. Lanier,et al.  CD40 preferentially costimulates activation of CD4+ T lymphocytes. , 1994, Journal of immunology.

[154]  S. Leong,et al.  Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. , 1999, Journal of immunotherapy.

[155]  M. Sakaguchi,et al.  Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. , 1996, The Journal of allergy and clinical immunology.

[156]  M. Milili,et al.  Rapid expansion of human immunoglobulin repertoire (VH, V kappa, V lambda) expressed in early fetal bone marrow. , 1990, The New biologist.

[157]  G. Beebe,et al.  FOLLOW‐UP STUDY ON ARMY PERSONNEL WHO RECEIVED ADJUVANT INFLUENZA VIRUS VACCINE 1951–1953 , 1964, American Journal of the Medical Sciences.

[158]  C. Weijer.  The future of research into rotavirus vaccine , 2000, BMJ : British Medical Journal.

[159]  R. May,et al.  Infectious Diseases of Humans: Dynamics and Control , 1991, Annals of Internal Medicine.

[160]  C. June,et al.  Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor‐mediated activation , 1989, European journal of immunology.

[161]  N. Flomenberg,et al.  Characterization of the alloreactivity and anti-leukemia reactivity of cord blood mononuclear cells. , 1995, Bone marrow transplantation.

[162]  L. Lanier,et al.  Requirements for CD28-dependent T cell-mediated cytotoxicity. , 1993, Journal of immunology.

[163]  A. Fischer,et al.  Undetectable CD40 ligand expression on T cells and low B cell responses to CD40 binding agonists in human newborns. , 1995, Journal of immunology.

[164]  D. Sesardic,et al.  European union regulatory developments for new vaccine adjuvants and delivery systems. , 2004, Vaccine.

[165]  M. Gold,et al.  Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. , 2004, Vaccine.

[166]  M. Lucero,et al.  Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants , 2003, The Pediatric infectious disease journal.

[167]  H. Tilg,et al.  Biologic activity of low dosage IL-2 treatment in vivo. Molecular assessment of cytokine network interaction. , 1994, Journal of immunology.

[168]  B. Vahlquist.  Response of infants to diphtheria immunization. , 1949, Lancet.

[169]  C. L. Silva,et al.  Vaccine adjuvant: it makes the difference. , 2004, Vaccine.

[170]  J. S. St. Geme,et al.  Immunologic response to early and routine DTP immunization in infants. , 1984, Pediatrics.

[171]  D. Greenberg,et al.  Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines. , 1995, The Journal of pediatrics.

[172]  E. Miller.  Measles-mumps-rubella vaccine and the development of autism. , 2003, Seminars in pediatric infectious diseases.

[173]  W. Göpel,et al.  Maturational Changes of Lymphocyte Surface Antigens in Human Blood: Comparison between Fetuses, Neonates and Adults , 2000, Neonatology.

[174]  C. Siegrist.  Neonatal and early life vaccinology. , 2001, Vaccine.

[175]  S. Akira,et al.  Toll-like receptors. , 2003, Annual review of immunology.

[176]  A. Batson,et al.  Win-win interactions between the public and private sectors , 1998, Nature Medicine.

[177]  C. Snapper,et al.  A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. , 1996, Journal of immunology.

[178]  N. Ariel,et al.  Search for Potential Vaccine Candidate Open Reading Frames in the Bacillus anthracis Virulence Plasmid pXO1: In Silico and In Vitro Screening , 2002, Infection and Immunity.

[179]  W. Keitel,et al.  Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. , 1994, Vaccine.

[180]  P. Beverley,et al.  In vitro responses of human CD45R0brightRA− and CD45R0−RAbright T cell subsets and their relationship to memory and naive T cells , 1997, European journal of immunology.

[181]  A. Rudin,et al.  Innate Immune Responses of Human Neonatal Cells to Bacteria from the Normal Gastrointestinal Flora , 2002, Infection and Immunity.

[182]  R. Schelonka,et al.  Regulation and chance in the ontogeny of B and T cell antigen receptor repertoires , 2002, Immunologic research.

[183]  A. Kruse,et al.  Failure to detect type 1 interferon production in human umbilical cord vein endothelial cells after viral exposure. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[184]  D. Reen,et al.  IL‐7 promotes the survival and maturation but not differentiation of human post‐thymic CD4+ T cells , 1998, European journal of immunology.

[185]  J. Donnelly,et al.  Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. , 1996, The Journal of pediatrics.

[186]  J. White,et al.  Treatment of aluminium hydroxide adjuvant to optimize the adsorption of basic proteins. , 1996, Vaccine.

[187]  A. Langmuir,et al.  THE CUTTER INCIDENT. POLIOMYELITIS FOLLOWING FORMALDEHYDE- INACTIVATED POLIOVIRUS VACCINATION IN THE UNITED STATES DURING THE SPRING OF 1955. II. RELATIONSHIP OF POLIOMYELITIS TO CUTTER VACCINE. , 1995 .

[188]  Ian T. Paulsen,et al.  Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[189]  M. Levine,et al.  Vaccination against typhoid fever: present status. , 1994, Bulletin of the World Health Organization.

[190]  C. Silverman,et al.  Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[191]  H. Takada,et al.  Structural requirements of lipid A for endotoxicity and other biological activities. , 1989, Critical reviews in microbiology.

[192]  Y. Maldonado,et al.  Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. , 2001, The Journal of infectious diseases.

[193]  E. Miller,et al.  Impact of meningococcal C conjugate vaccine in the UK. , 2002, Journal of medical microbiology.

[194]  L. Roberts.  Rotavirus Vaccines' Second Chance , 2004, Science.

[195]  D. Bishai,et al.  Measles vaccination improves the equity of health outcomes: evidence from Bangladesh. , 2003, Health economics.

[196]  S. Halstead,et al.  The future of dengue vaccines , 2002, The Lancet.

[197]  J. L. Fabio,et al.  Considerations for combination vaccine development and use in the developing world. , 2001 .

[198]  B. Schwartz,et al.  Intussusception among infants given an oral rotavirus vaccine. , 2001, The New England journal of medicine.

[199]  K. Sugamura,et al.  Expression of the interleukin-2 receptor gamma chain on cord blood mononuclear cells. , 1996, Blood.

[200]  Foege Wh,et al.  Mass vaccination programs in developing countries. , 1973 .

[201]  B. Dupont,et al.  Characterization of B cells in severe combined immunodeficiency disease. , 1989, Human immunology.

[202]  A A Hyder,et al.  Ethical review of health research: a perspective from developing country researchers , 2004, Journal of Medical Ethics.

[203]  A. Fattom,et al.  Prevention of invasive bacterial diseases by immunization with polysaccharide-protein conjugates. , 1989, Current topics in microbiology and immunology.

[204]  R. Belshe,et al.  Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. , 1993, The Journal of infectious diseases.

[205]  A. Barrett,et al.  Yellow fever vaccine , 2005, Expert review of vaccines.

[206]  J. Uhr,et al.  The antibody response to bacteriophage phi-X 174 in newborn premature infants. , 1962, The Journal of clinical investigation.

[207]  M. Stevenson,et al.  Early Therapy of Vertical Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Control of Viral Replication and Absence of Persistent HIV-1-Specific Immune Responses , 2000, Journal of Virology.

[208]  Y. Liu,et al.  Dendritic Cell Subsets and Lineages, and Their Functions in Innate and Adaptive Immunity , 2001, Cell.

[209]  G. Beebe,et al.  Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953. , 1972, American journal of epidemiology.

[210]  A. Cumano,et al.  The repertoires of circulating human CD8(+) central and effector memory T cell subsets are largely distinct. , 2003, Immunity.

[211]  M. Kremer,et al.  Perspectives on stimulating industrial research and development for neglected infectious diseases. , 2001, Bulletin of the World Health Organization.

[212]  D. Kasper,et al.  Conjugate vaccines against group B Streptococcus types IV and VII. , 2002, The Journal of infectious diseases.

[213]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[214]  E. Marcuse.  United States Vaccine Research: A Delicate Fabric of Public and Private Collaboration , 1998, Pediatrics.

[215]  T. Tedder,et al.  CD19, CD21, and CD22: Multifaceted Response Regulators of B Lymphocyte Signal Transduction , 2001, International reviews of immunology.

[216]  S Suissa,et al.  Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. , 2001, The New England journal of medicine.

[217]  Gupta,et al.  Aluminum compounds as vaccine adjuvants. , 1998, Advanced drug delivery reviews.

[218]  M. Rep,et al.  Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells , 1997, The Journal of experimental medicine.

[219]  Alan L Rothman,et al.  Dengue: defining protective versus pathologic immunity. , 2004, The Journal of clinical investigation.

[220]  V. Deneys,et al.  Age-related changes in human blood lymphocyte subpopulations. , 1992, The Journal of pediatrics.

[221]  G. Matyas,et al.  Immunologic approaches to the treatment of prostate cancer. , 1999, Seminars in oncology.

[222]  N. Begg,et al.  Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. , 1999, The Journal of infectious diseases.

[223]  Y. Shoenfeld,et al.  Vaccination and Autoimmunity , 2004 .

[224]  S. Jonjić,et al.  Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands , 1992, Journal of virology.

[225]  N. Bhardwaj,et al.  Dendritic cells resurrect antigens from dead cells. , 2001, Trends in immunology.

[226]  J. Poolman,et al.  Interferon-gamma and interleukin-6 augment the human in vitro antibody response to the Haemophilus influenzae type b polysaccharide. , 1992, The Journal of infectious diseases.

[227]  A. Sher,et al.  Heat-Killed Brucella abortus Induces TNF and IL-12p40 by Distinct MyD88-Dependent Pathways: TNF, Unlike IL-12p40 Secretion, Is Toll-Like Receptor 2 Dependent , 2003, The Journal of Immunology.

[228]  C. Alving,et al.  Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. , 1993, Immunobiology.

[229]  D. Reen,et al.  Signalling via CD28 of human naive neonatal T lymphocytes , 1995, Clinical and experimental immunology.

[230]  J. Tikerpae,et al.  Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. , 1992, Journal of immunology.

[231]  G. Matyas,et al.  Skin immunization made possible by cholera toxin , 1998, Nature.

[232]  F. Jensen,et al.  Adjuvant activity of incomplete Freund's adjuvant. , 1998, Advanced drug delivery reviews.

[233]  J. Bines,et al.  Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. , 2004, Vaccine.

[234]  M. Osterholm,et al.  Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. , 1993, The Journal of pediatrics.

[235]  J. Eskola,et al.  Early immunization with conjugate vaccines. , 1998, Vaccine.

[236]  M. Lipsitch.  Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. , 1999, Emerging infectious diseases.

[237]  C. Snapper,et al.  B‐cell activation by T‐cell‐independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms , 2000, Immunological reviews.

[238]  B. Gandevia,et al.  DECLARATION OF HELSINKI , 1964, Definitions.

[239]  C. Conlon,et al.  The ethics of research related to health care in developing countries , 2004, Journal of Medical Ethics.

[240]  B. Pulendran.  Modulating vaccine responses with dendritic cells and Toll‐like receptors , 2004, Immunological reviews.

[241]  P. Kourilsky,et al.  Recombinant viruses as a tool for therapeutic vaccination against human cancers. , 2000, Immunology letters.

[242]  C. Fairley,et al.  Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. , 1996, The Journal of infectious diseases.

[243]  C. Pearson.  Development of Arthritis, Periarthritis and Periostitis in Rats Given Adjuvants.∗ , 1956, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[244]  K. Chumakov,et al.  Increased safety level of serotype 3 Sabin oral poliomyelitis vaccine lots by improved seed virus, and tissue culture and virus infection conditions. , 2000, Vaccine.

[245]  B D Hall,et al.  Synthesis and assembly of hepatitis B virus surface antigen particles in yeast , 1982, Nature.

[246]  E. Gotschlich,et al.  Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. , 1979, The Journal of infectious diseases.

[247]  I. Sanz,et al.  Multiple mechanisms participate in the generation of diversity of human H chain CDR3 regions. , 1991, Journal of immunology.

[248]  T. Braciale,et al.  Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract , 2002, Nature Medicine.

[249]  J. M. Morrison,et al.  Hepatitis B Vaccine , 1980, The Lancet.

[250]  Y. Maldonado,et al.  Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. , 1998, JAMA.

[251]  E. Padlan,et al.  Anatomy of the antibody molecule. , 1994, Molecular immunology.

[252]  F. Sallusto,et al.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells , 2000, Nature Immunology.

[253]  S. Cochi,et al.  The Vaccine Adverse Event Reporting System (VAERS). , 1994, Vaccine.

[254]  G. Aversa,et al.  Induction of isotype switching and Ig production by CD5+ and CD10+ human fetal B cells. , 1992, Journal of immunology.

[255]  R. Schmidt,et al.  MEASLES IMMUNIZATION WITH KILLED VIRUS VACCINE. SERUM ANTIBODY TITERS AND EXPERIENCE WITH EXPOSURE TO MEASLES EPIDEMIC. , 1965, American journal of diseases of children.

[256]  B. O'brien,et al.  Willingness to Pay , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[257]  Antonio Lanzavecchia,et al.  Regulation of T Cell Immunity by Dendritic Cells , 2001, Cell.

[258]  J. White,et al.  Effect of adsorbed carbonate on surface charge characteristics and physical properties of aluminum hydroxide gel. , 1981, Journal of pharmaceutical sciences.

[259]  E. Heiligenstein,et al.  Antibody response to oral polio vaccine in premature infants. , 1983, The Journal of pediatrics.

[260]  Z. Bhutta,et al.  Ethics in international health research: a perspective from the developing world. , 2002, Bulletin of the World Health Organization.

[261]  D. Lewis,et al.  Impaired Accumulation and Function of Memory CD4 T Cells in Human IL-12 Receptor β1 Deficiency1 , 2003, The Journal of Immunology.

[262]  P. Aaby,et al.  Vaccinated children get milder measles infection: a community study from Guinea-Bissau. , 1986, The Journal of infectious diseases.

[263]  M. McElrath,et al.  Selection of potent immunological adjuvants for vaccine construction. , 1995, Seminars in cancer biology.

[264]  A. Steere,et al.  Autoimmune mechanisms in antibiotic treatment-resistant lyme arthritis. , 2001, Journal of autoimmunity.

[265]  J. Milstien.  Regulation of vaccines: strengthening the science base , 2004, Journal of public health policy.

[266]  P. Griffiths,et al.  Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. , 1999, The Journal of infectious diseases.

[267]  C. Wheeler,et al.  Polyreactive antigen‐binding B cells are the predominant cell type in the newborn B cell repertoire , 1998, European journal of immunology.

[268]  I. T. Ten Berge,et al.  Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. , 2000, The Journal of clinical investigation.

[269]  M. Atkins.  Interleukin-2: clinical applications. , 2002, Seminars in oncology.

[270]  E. Miller,et al.  Impact of anti-vaccine movements on pertussis control: the untold story , 1998, The Lancet.

[271]  D. West,et al.  Clinical experience with hepatitis B vaccines. , 1989, American journal of infection control.

[272]  A. Hightower,et al.  Immunization of US children with Hemophilus influenzae type b polysaccharide vaccine. A cost-effectiveness model of strategy assessment. , 1985, JAMA.

[273]  S. Plotkin,et al.  Six Revolutions in Vaccinology , 2005, The Pediatric infectious disease journal.

[274]  M. Kieny,et al.  Immunization safety priority project at the World Health Organization. , 2003, Seminars in pediatric infectious diseases.

[275]  P. Lydon,et al.  Financial challenges of immunization: a look at GAVI. , 2004, Bulletin of the World Health Organization.

[276]  C. Snapper,et al.  Bacterial lipoproteins may substitute for cytokines in the humoral immune response to T cell-independent type II antigens. , 1995, Journal of immunology.

[277]  M Schwanig,et al.  Elimination of abnormal toxicity test for sera and certain vaccines in the European Pharmacopoeia. , 1997, Vaccine.

[278]  Robert T. Chen,et al.  Standardized case definitions of adverse events following immunization (AEFI). , 2004, Vaccine.

[279]  M. Osterholm,et al.  Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. , 1992, JAMA.

[280]  L. Picker,et al.  Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. , 2002, The Journal of infectious diseases.

[281]  M. Clements,et al.  Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or PreS2 + S antigens. , 1994, The Journal of infectious diseases.

[282]  Davenport Fm.  Seventeen years' experience with mineral oil adjuvant influenza virus vaccines. , 1968 .

[283]  J. Wenger.  Vaccines for the developing world: current status and future directions. , 2001, Vaccine.

[284]  S. Rowland-Jones,et al.  Mature CD8(+) T lymphocyte response to viral infection during fetal life. , 2003, The Journal of clinical investigation.

[285]  F. André.  Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. , 1990, Vaccine.

[286]  Theresa M. Wizemann,et al.  Use of a Whole Genome Approach To Identify Vaccine Molecules Affording Protection against Streptococcus pneumoniae Infection , 2001, Infection and Immunity.

[287]  S. Antonenko,et al.  Generation of primary antigen-specific human T- and B-cell responses in immunocompetent SCID-hu mice , 2000, Nature Medicine.

[288]  P. Borrow,et al.  Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon , 2003, Nature Immunology.

[289]  R. Fleischmann,et al.  Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. , 1995, Science.

[290]  J. Wedgwood,et al.  Umbilical cord blood lacks circulating B lymphocytes expressing surface IgG or IgA. , 1997, Clinical immunology and immunopathology.

[291]  A. Shearley,et al.  The societal value of vaccination in developing countries. , 1999, Vaccine.

[292]  N. Begg,et al.  Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine , 2000, Epidemiology and Infection.

[293]  G. Siber,et al.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[294]  N. Andrews,et al.  Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England , 2001, The Lancet.

[295]  I. Feavers,et al.  Development of vaccines against meningococcal disease , 2002, The Lancet.

[296]  H. Stoddart,et al.  Parents' perspectives on the MMR immunisation: a focus group study. , 2001, The British journal of general practice : the journal of the Royal College of General Practitioners.

[297]  J. Jacobberger,et al.  Reduced NFAT1 protein expression in human umbilical cord blood T lymphocytes. , 1999, Blood.

[298]  G. Matyas,et al.  Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins as Antigens and Adjuvants , 1999, Infection and Immunity.

[299]  H. Varmus,et al.  Ethical complexities of conducting research in developing countries. , 1997, The New England journal of medicine.

[300]  J. Shiloach,et al.  Safety and Immunogenicity of ImprovedShigella O-Specific Polysaccharide-Protein Conjugate Vaccines in Adults in Israel , 2001, Infection and Immunity.

[301]  P. Razzell.  The conquest of smallpox , 1977 .

[302]  Katsuaki Sato,et al.  Chemokine Receptor Expressions and Responsiveness of Cord Blood T Cells , 2001, The Journal of Immunology.

[303]  L. Baraff,et al.  IgG and IgG Subclass Specific Antibody Responses to Diphtheria and Tetanus Toxoids in Newborns and Infants Given DTP Immunization , 1986, Pediatric Research.

[304]  B. Vastag.  Helsinki discord? A controversial declaration. , 2000, JAMA.

[305]  J. Gralow,et al.  Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. , 1996, Blood.

[306]  Rajesh K. Gupta,et al.  Adjuvants--a balance between toxicity and adjuvanticity. , 1993, Vaccine.

[307]  P. Lydyard,et al.  The Antibody Repertoire of Early Human B Cells , 1990, Scandinavian journal of immunology.

[308]  S. Emerson,et al.  Leu-1+ (CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: phenotypic and functional studies. , 1986, Journal of immunology.

[309]  D. Sack,et al.  The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. , 1991, The New England journal of medicine.

[310]  R. Belshe,et al.  Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults , 1994, Infection and immunity.

[311]  Michael Kremer,et al.  Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases , 2004 .

[312]  Patricia L. Marshall,et al.  The Decision Dynamics of Clinical Research: The Context and Process of Informed Consent , 2002, Medical care.

[313]  G. Wilson.  The Hazards of Immunization , 2000 .

[314]  A. Hinman.  Economic aspects of vaccines and immunizations. , 1999, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[315]  David Parkin,et al.  Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.

[316]  J. Clemens,et al.  The vaccine data link in Nha Trang, Vietnam: a progress report on the implementation of a database to detect adverse events related to vaccinations. , 2003, Vaccine.

[317]  P. van Damme,et al.  Methodological issues and new developments in the economic evaluation of vaccines , 2003, Expert review of vaccines.

[318]  A. Washington,et al.  Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. , 1988, JAMA.

[319]  R. Steinbrook.  The AIDS epidemic in 2004. , 2004, The New England journal of medicine.

[320]  L. Finelli,et al.  Increased Susceptibility to Measles in Infants in the United States , 1999, Pediatrics.

[321]  P. Scott,et al.  IL‐12: Keeping Cell‐Mediated Immunity Alive , 2001, Scandinavian journal of immunology.

[322]  S. Black,et al.  Efficacy of pneumococcal conjugate vaccines in large scale field trials , 2000, The Pediatric infectious disease journal.

[323]  N. Teig,et al.  Age‐Related Changes in Human Blood Dendritic Cell Subpopulations , 2002, Scandinavian journal of immunology.

[324]  B. Zegers,et al.  Infant B cell responses to polysaccharide determinants. , 1998, Vaccine.

[325]  Susana Vázquez,et al.  Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. , 2002, Revista panamericana de salud publica = Pan American journal of public health.

[326]  D. Reen,et al.  Cord blood CD4⊃ CD45RA⊃ T cells achieve a lower magnitude of activation when compared with their adult counterparts , 1997, Immunology.

[327]  Joy A. Cavagnaro,et al.  Preclinical safety evaluation of biotechnology-derived pharmaceuticals , 2002, Nature Reviews Drug Discovery.

[328]  S. Fossum.  The life history of dendritic leukocytes (DL). , 1989, Current topics in pathology. Ergebnisse der Pathologie.

[329]  放射線影響研究所.  Technical report series , 1989 .

[330]  C. Alving,et al.  Transcutaneous immunization: A human vaccine delivery strategy using a patch , 2000, Nature Medicine.

[331]  J. Bellanti,et al.  The development of the immune response. Studies on the agglutinin response to Salmonella flagellar antigens in the newborn rabbit. , 1963 .

[332]  P. Lambert,et al.  Determinants of infant responses to vaccines in presence of maternal antibodies. , 1998, Vaccine.

[333]  L. Ball,et al.  Prelicensure evaluation of combination vaccines. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[334]  Phillip R Pittman,et al.  Aluminum-containing vaccine associated adverse events: role of route of administration and gender. , 2002, Vaccine.

[335]  J. Keyser,et al.  Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis , 1998, Journal of the Neurological Sciences.

[336]  M. Newport,et al.  Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. , 1999, Journal of immunology.

[337]  J. Shiloach,et al.  The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. , 2001, The New England journal of medicine.

[338]  T. Monath,et al.  Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases , 2001, The Lancet.

[339]  L. Richter,et al.  Ethical issues in HIV vaccine trials in South Africa. , 2000, South African journal of science.

[340]  C. Drakeley,et al.  Efficacy trial of malaria vaccine SPf66 in Gambian infants , 1995, The Lancet.

[341]  M. Cooper,et al.  Immunofluorescent studies of the development of pre‐B cells, B lymphocytes and immunoglobulin isotype diversity in humans , 1977, European journal of immunology.

[342]  N. Halsey.  VACCINE SAFETY: REAL AND PERCEIVED ISSUES , 2003 .

[343]  D. Reen,et al.  Reduced primary antigen‐specific T‐cell precursor frequencies in neonates is associated with deficient interleukin‐2 production , 1996, Immunology.

[344]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[345]  M. Mescher.  Molecular Interactions in the Activation of Effector and Precursor Cytotoxic T Lymphocytes , 1995, Immunological reviews.

[346]  P. Beutels.  Economic evaluation of vaccination programmes in humans: a methodological exploration with applications to hepatitis B, varicella-zoster, measles, pertussis, hepatitis A and pneumococcal vaccination , 2002 .

[347]  A. Sher,et al.  A Critical Role for IL-21 in Regulating Immunoglobulin Production , 2002, Science.

[348]  J. Sullivan,et al.  Early HIV-1 Envelope-specific Cytotoxic T Lymphocyte Responses in Vertically Infected Infants , 1997, The Journal of experimental medicine.

[349]  M. Goldman,et al.  Bordetella pertussis toxin induces the release of inflammatory cytokines and dendritic cell activation in whole blood: impaired responses in human newborns , 2002, European journal of immunology.

[350]  C. Alving.  Design and selection of vaccine adjuvants: animal models and human trials. , 2002, Vaccine.

[351]  Yingdong Zhao,et al.  Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease , 1999, Nature Medicine.

[352]  L. Ball,et al.  An assessment of thimerosal use in childhood vaccines. , 2001, Pediatrics.

[353]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[354]  H. Maguire,et al.  Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. , 1986, Cancer research.

[355]  S. Poppema,et al.  Fetal and neonatal development of human spleen: an immunohistological study. , 1987, Immunology.

[356]  R. Gupta,et al.  Adjuvants for human vaccines--current status, problems and future prospects. , 1995, Vaccine.

[357]  C. Tacket,et al.  SAFETY, IMMUNOGENICITY, AND EFFICACY OF RECOMBINANT LIVE ORAL CHOLERA VACCINES, CVD 103 AND CVD 103-HgR , 1988, The Lancet.

[358]  A. Schuchat,et al.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. , 2001, JAMA.

[359]  L. Frenkel,et al.  Ontogeny of phytohemagglutinin-induced gamma interferon by leukocytes of healthy infants and children: evidence for decreased production in infants younger than 2 months of age. , 1987, The Journal of pediatrics.

[360]  S. Kumar,et al.  Adverse reactions after measles vaccination in India. , 1995, The National medical journal of India.

[361]  V. Maino,et al.  Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. , 1995, Blood.

[362]  S. Marshall‐Clarke,et al.  Functional responses of human neonatal B lymphocytes to antigen receptor cross‐linking and CpG DNA , 2003, Clinical and experimental immunology.

[363]  S. Adler.  The molecular epidemiology of cytomegalovirus transmission among children attending a day care center. , 1985, The Journal of infectious diseases.

[364]  Vaccination in tomorrow's society. , 2003, The Lancet. Infectious diseases.

[365]  Robert T. Chen,et al.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. , 2004, The New England journal of medicine.

[366]  M. Drummond.  Output Measurement for Resource Allocation Decisions in Health Care , 1989 .

[367]  R. Rappuoli,et al.  SARS — beginning to understand a new virus , 2003, Nature Reviews Microbiology.